Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 12.6%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totalling 628,300 shares, a drop of 12.6% from the May 31st total of 718,900 shares. Based on an average daily volume of 121,800 shares, the short-interest ratio is presently 5.2 days. Currently, 4.1% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of BriaCell Therapeutics in a research note on Tuesday, June 4th.

Hedge Funds Weigh In On BriaCell Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BCTX. Onyx Bridge Wealth Group LLC purchased a new stake in BriaCell Therapeutics during the 4th quarter valued at about $176,000. K.J. Harrison & Partners Inc grew its position in shares of BriaCell Therapeutics by 22.1% in the fourth quarter. K.J. Harrison & Partners Inc now owns 80,715 shares of the company’s stock valued at $476,000 after purchasing an additional 14,625 shares in the last quarter. Finally, National Bank of Canada FI grew its position in shares of BriaCell Therapeutics by 200.0% in the fourth quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after purchasing an additional 5,000 shares in the last quarter. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Price Performance

Shares of BriaCell Therapeutics stock opened at $1.14 on Monday. The business has a 50 day simple moving average of $1.66 and a two-hundred day simple moving average of $2.94. BriaCell Therapeutics has a 12 month low of $0.95 and a 12 month high of $7.59.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings data on Friday, June 14th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.55) by $0.66. On average, research analysts predict that BriaCell Therapeutics will post -1.39 EPS for the current fiscal year.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.